DON’T DIVIDE THE DOSE: ONCE DAILY (QD) AND TWICE DAILY (BID) EARLY CYCLE GONADOTROPIN (GND) DOSING HAVE EQUIVALENT ASSISTED REPRODUCTIVE TECHNOLOGY (ART) OUTCOMES– A QUALITY IMPROVEMENT (QI) PROJECT

Abstract

For more than 25 years, our academic fertility center has prescribed GNDs BID between cycle start and the next monitoring visit 2-5 days later, when QD dosing is initiated. However, BID dosing is more complicated, leads to more medication errors and is less preferred by patients1. Studies evaluating the impact of GND timing on ART outcomes are limited and outdated2-4. Thus, we performed a QI project to assess whether changing early GND dosing to QD impacted ART outcomes.